Anixa Biosciences Inc (ANIX)
Anixa Biosciences develops cancer therapies and vaccines, mainly for ovarian and breast cancer, and is based in San Jose, California. It last closed at $2.67 on Nov 17, up 4.71% on the day. ANIX reports earnings on Mon, Jan 11, 2027.
Key Stats
Last 12 monthsNot reported for this period.
From ANIX's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on ANIX in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $2.67.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 22 | HC Wainwright & Co. | Maintained | Buy | $6 |
| Jun 30 | D. Boral Capital | Assumed coverage | Buy | $10 |
Technical Analysis
The stock is 11% below its 20 day and 7% below its 50 day average. It is 11% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the swing low (Sep 10) at $2.66, and the nearest resistance the Pivot R1 at $2.74.
| RSI (14) | 42.22 | Middle of its range | Neutral |
| MACD | -0.06 | Below its signal line | Bearish |
| Stochastic | 7.1 | Near the bottom of its range | Oversold |
| ADX (14) | 22.2 | Weak trend | |
| Williams %R | -85.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -110.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −12.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.19 | Typical daily range, 7.1% of price |
| RSI (14) | 43.91 | Middle of its range | Neutral |
| MACD | -0.07 | Below its signal line | Bearish |
| Stochastic | 20.4 | Middle of its range | Neutral |
| ADX (14) | 12.7 | No clear trend | |
| Williams %R | -90.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -114.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −3.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.41 | Typical daily range, 15.5% of price |
What happened before
See how ANIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ANIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ANIX in the last 90 days.
ANIX Institutional Ownership
Full report →- ▲34 buying vs 13 selling
- ▲Held by funds +2.9 pts
- ▲Funds holding +11
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 75 | 64 | +17.2% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 18.4% | 15.4% | +2.9 pts |
| New / increased | 14 / 20 | 11 / 16 | +25.9% |
| Reduced / sold out | 9 / 4 | 7 / 7 | −7.1% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANIX is in one of them and how their past ANIX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ANIX in an article yet. Here's the latest on the wider market.
About Anixa Biosciences
Anixa Biosciences is a biotechnology company based in San Jose, California, that is developing cancer therapies and vaccines. Its main programs focus on ovarian cancer and breast cancer, including a cell therapy designed to treat ovarian cancer and a vaccine aimed at preventing and treating breast cancer. Its products are still being tested in clinical trials and are not yet available for sale.
- Headquarters
- San Jose, CA

